20:02:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Chemoswed är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom utveckling av analytiska program. Produktportföljen är bred och inkluderar exempelvis program för intern uppföljning, process- samt systemhantering. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster inom arbetsområdet. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Magle Chemoswed har sitt huvudkontor i Malmö.

Kalender

2023-04-26 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-12-14 Extra Bolagsstämma 2021
2021-11-16 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-14 Kvartalsrapport 2021-Q1
2021-05-03 Ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Extra Bolagsstämma 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-07-14 Kvartalsrapport 2020-Q2

Prenumeration

2022-05-18 09:00:00

The Magle Group’s sponsorship of the SmiLe incubator is part of the Group’s commitment to supporting early-stage companies develop and commercialize new ideas in life science

The sponsorship of SmiLe in 2022 is part of Magle Group’s commitment to being a group that is truly a partner in addressing the healthcare challenges in the world. As part of the sponsorship Magle Group will provide advisory and development support for innovation companies and aims to help companies navigate the complexities of product development in the life science sector.

“At Magle Chemoswed we understand the risk and complexity around the development of a pharmaceutical candidate. Our right first-time philosophy has been tested and proven over numerous projects. As a one-stop shop we offer fully integrated services from early screening, solid state analysis, risk assessments, process development, formulation, and production for clinical trials, tox testing, pre-clinical testing all the way to validation and commercial supply. By sharing our experiences and knowledge we believe that we can make a positive difference to SmiLe companies,” said Simon Jegou, Chief Strategy Officer, Magle Group.

"I am very pleased to announce our new gold sponsorship collaboration with Magle Chemoswed. They bring completely new and valuable expertise to our community and they complement our existing sponsors perfectly. I am convinced that this will be of great benefit to our member companies and I am very much looking forward to our cooperation," said Ebba Fåhraeus, CEO of SmiLe.

More information about SmiLe can be found here